References

Classical Hodgkin lymphoma

10.1016/s0140-6736(20)32207-8 · 2021 · External reference

Anaplastic large cell lymphoma: molecular pathogenesis and treatment

10.3390/cancers14071650 · 2022 · External reference

Clinical advances in epigenetic therapies for lymphoma

10.1186/s13148-023-01452-6 · 2023 · External reference

Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma

10.1016/j.bbmt.2006.06.006 · 2006 · External reference

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

10.1200/jco.2010.29.9024 · 2011 · External reference

Challenges of driving CD30-directed CAR-T cells to the clinic

10.1186/s12885-019-5415-9 · 2019 · External reference

CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy

10.1182/blood.v85.1.1.bloodjournal8511 · 1995 · External reference

Prognostic significance of CD30 expression in diffuse large B-cell lymphoma: a systematic review with meta-analysis

10.1111/jop.13208 · 2021 · External reference

Clinicopathologic features and survival outcomes of CD30 expression in extranodal natural killer/T-cell lymphoma

10.1093/ajcp/aqae012 · 2024 · External reference

CD30: expression and function in health and disease

10.1006/smim.1998.0156 · 1998 · External reference

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma

10.1200/jco.2011.38.0410 · 2012 · External reference

Therapeutic use of brentuximab vedotin in CD30+ hematologic malignancies

10.2174/1871520616666160902100506 · 2017 · External reference

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

10.1182/blood-2014-08-595801 · 2015 · External reference

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

10.1182/blood-2016-02-699850 · 2016 · External reference

Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes

10.1172/jci94306 · 2017 · External reference

Long-term follow-up of combination of B-cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma

10.1200/jco.21.01676 · 2022 · External reference

Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

10.1182/blood.2021013733 · 2022 · External reference

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

10.1016/s1470-2045(18)30864-7 · 2019 · External reference

Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma

10.1038/s41392-023-01702-2 · 2024 · External reference

Autologous stem cell transplantation in tandem with anti-CD30 CAR T-cell infusion in relapsed/refractory CD30+ lymphoma

10.1186/s40164-022-00323-9 · 2022 · External reference

Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients

10.1038/s41408-020-0274-9 · 2020 · External reference

Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma

10.1200/jco.20.01342 · 2020 · External reference

Superior therapeutic index in lymphoma therapy: CD30(+) CD34(+) hematopoietic stem cells resist a chimeric antigen receptor T-cell attack

10.1038/mt.2016.82 · 2016 · External reference

Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial

10.1158/1078-0432.ccr-16-1365 · 2017 · External reference

Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study

10.1016/s2352-3026(24)00064-4 · 2024 · External reference

Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed/refractory CD30+ lymphoma

10.3389/fimmu.2022.858021 · 2022 · External reference

The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity

10.1038/s41598-022-14523-0 · 2022 · External reference

ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells

10.1016/j.bbmt.2018.12.758 · 2019 · External reference

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification

10.1200/jco.2013.54.8800 · 2014 · External reference

Tumor buster - where will the CAR-T cell therapy ‘missile’ go?

10.1186/s12943-022-01669-8 · 2022 · External reference

Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia

10.1002/cncr.35316 · 2024 · External reference

Humanized anti-CD19 CAR-T cell therapy and sequential allogeneic hematopoietic stem cell transplantation achieved long-term survival in refractory and relapsed B lymphocytic leukemia: a retrospective study of CAR-T cell therapy

10.3389/fimmu.2021.755549 · 2021 · External reference

Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL

10.1182/hematology.2023000422 · 2023 · External reference

CAR-T cell therapy: the efficacy and toxicity balance

10.1007/s11899-023-00687-7 · 2023 · External reference

Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies

10.3389/fimmu.2020.01973 · 2020 · External reference

Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma

10.1177/20406207241237594 · 2024 · External reference